Literature DB >> 9195294

A comparison of the uricosuric effects in rats of diltiazem and derivatives of dihydropyridine (nicardipine and nifedipine).

H Sugino1, H Shimada.   

Abstract

The effects of nicardipine and nifedipine on the urinary excretion of urate were examined in rats and compared with those of diltiazem. Test drugs were administered to urethane-anesthetized oxonate-loaded rats by continuous i.v. infusion. Diltiazem (10 micrograms/rat/min), nicardipine (0.3 microgram/rat/min) and nifedipine (1.0 microgram/rat/min) caused similar reductions of systemic blood pressure and increased total renal blood flow. Diltiazem did not increase urine volume significantly. However, this drug produced obvious uricosuria, with a significant increase in the ratio of urate clearance to inulin clearance (Cua/Cin), which resulted from an increase in Cua, but not from changes in the glomerular filtration rate (GFR). Nicardipine had clear diuretic and uricosuric effects, with similar increases in Cua and GFR and, thus, no change in Cua/Cin. On the other hand, nifedipine did not have any significant effect on the renal handling of urate. These results suggest that nicardipine produces uricosuria in rats via alterations in renal hemodynamics, while the uricosuric effect of diltiazem involves the tubules, as well as alterations in renal hemodynamics.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9195294     DOI: 10.1254/jjp.74.29

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  2 in total

Review 1.  Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used Medications.

Authors:  Nicole Leung; Kevin Yip; Michael H Pillinger; Michael Toprover
Journal:  Mayo Clin Proc       Date:  2022-07       Impact factor: 11.104

2.  The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

Authors:  Stephen P Juraschek; Lara M Simpson; Barry R Davis; Robert H Shmerling; Jennifer L Beach; Anthony Ishak; Kenneth J Mukamal
Journal:  J Hypertens       Date:  2020-05       Impact factor: 4.776

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.